Inactive Instrument

Fibrocell Science Inc OTC Bulletin Board

Equities

US3157211000

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

2019	Fibrocell Science, Inc.(NasdaqGM:FCSC) dropped from S&P TMI Index	CI
2019	Fibrocell Science, Inc.(NasdaqGM:FCSC) dropped from NASDAQ Composite Index	CI

Fibrocell Science, Inc. : to Present at the 5th Annual OneMedForum San Francisco 2012

January 04, 2012 at 01:10 pm

MarketScreener.com By

Fibrocell Science, Inc. (OTCBB: FCSC), a biotechnology company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications, announced today that David Pernock, the Company's Chairman and CEO, will be presenting at the 5^th Annual OneMedForum San Francisco 2012 to be held on January 9-12 at The Sir Francis Drake Hotel.

Fibrocell's presentation is scheduled for Wednesday, January 11, 2012 at 10:00 AM Pacific Time.

The presentation will be webcast live, and a replay will be available during the week of January 9 at www.onemedplace.com.

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (OTCBB: FCSC) is a biotechnology company focused on the development of regenerative cell therapy for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well as its innovative cellular processing technology and manufacturing excellence. For additional information, please visit www.fibrocellscience.com.

Media
Marina Maher Communications
Jessica Morrison
212-485-6806
jmorrison@mahercomm.com
or
Investors
ICR, LLC
Sherry Bertner
Managing Director
646-277-1247
Sherry.Bertner@icrinc.com

Latest news about Fibrocell Science Inc

Fibrocell Science, Inc.(NasdaqGM:FCSC) dropped from S&P TMI Index	16/12/19	CI
Fibrocell Science, Inc.(NasdaqGM:FCSC) dropped from NASDAQ Composite Index	13/12/19	CI
Castle Creek Pharmaceutical Holdings, Inc. completed the acquisition of Fibrocell Science, Inc..	12/12/19	CI
Fibrocell Science, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	14/11/19	CI
Castle Creek Pharmaceutical Holdings, Inc. entered into a definitive agreement to acquire Fibrocell Science, Inc. for $63.3 million.	11/09/19	CI
Fibrocell Science, Inc Appoints Sean D. Buckley as Chief Financial Officer	22/08/19	CI
Fibrocell Science, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	14/08/19	CI
Fibrocell Science, Inc. Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEB	29/05/19	CI
Fibrocell Science, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	15/05/19	CI
Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy	15/04/19	CI
Fibrocell Science, Inc. Reports Earnings Results for the Full Year Ended December 31, 2018	27/03/19	CI
Fibrocell Announces Positive Feedback from Type B End-of-Phase 2 Meeting with FDA on Phase 3 Clinical Trial Design for FCX-007	27/03/19	CI
Fibrocell Science, Inc. Auditor Raises 'Going Concern' Doubt	26/03/19	CI
Fibrocell Science, Inc. announced that it has received $0.9 million in funding from EB Research Partnership, Inc., Endowment Arm, Epidermolysis Bullosa Medical Research Foundation, Endowment Arm	10/12/18	CI
Fibrocell Science, Inc. announced that it expects to receive $0.9 million in funding from EB Research Partnership, Inc., Endowment Arm, Epidermolysis Bullosa Medical Research Foundation, Endowment Arm	06/12/18	CI
Fibrocell Science, Inc. Reports Consolidated Unaudited Earnings Results for the Nine Months Ended September 30, 2018	13/11/18	CI
Fibrocell Science, Inc. Receives Guidance from FDA on Phase 3 Clinical Trial Design for FCX-007	25/10/18	CI
Fibrocell Science, Inc. Announces U.S. Food and Drug Administration Granted Fast Track Designation to FCX-013	05/09/18	CI
Fibrocell Science, Inc. Announces Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2018; Expects to Enroll A Total of Six Patients Ages Seven and Older by the End of the Third Quarter of 2018	09/08/18	CI
Fibrocell Science, Inc. announced that it has received $0.119769 million in funding	04/07/18	CI
Fibrocell Science, Inc. announced that it expects to receive $0.119769 million in funding	01/07/18	CI
Fibrocell Science, Inc. Appoints Sean D. Buckley as Vice President of Business Administration and Corporate Secretary	22/06/18	CI
Fibrocell Science, Inc. announced that it has received $0.191084 million in funding	30/05/18	CI
Fibrocell Science, Inc. announced that it expects to receive $0.191084 million in funding	28/05/18	CI
Fibrocell Science, Inc. Provides an Update on Interim Results and Progress of its Phase 1/2 Clinical Trial of FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa	21/05/18	CI

Chart Fibrocell Science Inc

Duration

Period

More charts

Company Profile

Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+24.62%	46.56B
LONZA GROUP AG	+45.38%	41.67B
IQVIA HOLDINGS INC.	-0.08%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+33.26%	32.4B
ICON PUBLIC LIMITED COMPANY	+20.49%	28.18B
CELLTRION, INC.	-6.35%	28.1B
UNITED THERAPEUTICS CORPORATION	+49.06%	14.52B
MEDPACE HOLDINGS, INC.	+47.20%	13.74B
BIO-TECHNE CORPORATION	+1.97%	12.17B

Other Biotechnology & Medical Research